|
|
 |
Antineoplastic agent
|
 |
Antimetabolite
|
 |
Capecitabine is taken cyclically (2 weeks on, 1 week off). Adults: usually, 2,500 mg per square meter of body surface in two divided doses (12 hours apart) a day. The dose and duration of treatment can be adjusted by your oncologist while in therapy.
|
 |
Category D
|
 |
Diarrhea, abdominal pain, Constipation, Dehydration, loss of appetite, skin rash, dry or itchy skin, headache, sores or ulcers in mouth, numbness or tingling sensation on palms and soles, fever, anemia
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
 |
|
|
